Intervacc AB (IVACC) - Total Liabilities
Based on the latest financial reports, Intervacc AB (IVACC) has total liabilities worth Skr18.76 Million SEK (≈ $2.02 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Intervacc AB to assess how effectively this company generates cash.
Intervacc AB - Total Liabilities Trend (2013–2024)
This chart illustrates how Intervacc AB's total liabilities have evolved over time, based on quarterly financial data. Check IVACC cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Intervacc AB Competitors by Total Liabilities
The table below lists competitors of Intervacc AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Firetrade Engineering PCL
BK:FTE
|
Thailand | ฿387.68 Million |
|
Far East Fame Line DDB Public Company Limited
BK:FE
|
Thailand | ฿322.08 Million |
|
Eclipse Metals Ltd
AU:EPM
|
Australia | AU$120.79K |
|
Actoz Soft Co.Ltd
KQ:052790
|
Korea | ₩127.88 Billion |
|
Australian Unity Office Fund
AU:AOF
|
Australia | AU$815.00K |
|
Done.ai Group AB
ST:TINGS-B
|
USA | Skr2.15 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Intervacc AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Intervacc AB (IVACC) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intervacc AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intervacc AB (2013–2024)
The table below shows the annual total liabilities of Intervacc AB from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr24.99 Million ≈ $2.69 Million |
+15.26% |
| 2023-12-31 | Skr21.68 Million ≈ $2.33 Million |
+45.74% |
| 2022-12-31 | Skr14.88 Million ≈ $1.60 Million |
-29.63% |
| 2021-12-31 | Skr21.14 Million ≈ $2.28 Million |
+19.63% |
| 2020-12-31 | Skr17.67 Million ≈ $1.90 Million |
+2.48% |
| 2019-12-31 | Skr17.25 Million ≈ $1.86 Million |
+40.97% |
| 2018-12-31 | Skr12.23 Million ≈ $1.32 Million |
-17.03% |
| 2017-12-31 | Skr14.74 Million ≈ $1.59 Million |
-55.95% |
| 2016-12-31 | Skr33.47 Million ≈ $3.60 Million |
+17.72% |
| 2015-12-31 | Skr28.44 Million ≈ $3.06 Million |
-46.08% |
| 2014-12-31 | Skr52.74 Million ≈ $5.68 Million |
+4143.19% |
| 2013-12-31 | Skr1.24 Million ≈ $133.76K |
-- |
About Intervacc AB
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages… Read more